Meeting Tue, 01/16/2024 - 12:00 Drug Prior Authorization Committee Meeting Information

Date
Media
Edit Implementation Schedule January 2024
Conduent Reports January 2024
New Drugs January 2024
PDL Announcements January 2024
PDL Recommendations January 2024
MO Pharmacy Advisory Boards Slides January 2024
MO HealthNet Division BPM Report
Agenda
DPAC Agenda January 2024
Minutes
DPAC Minutes January 2024 Approved
Criteria
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Benzodiazepines Select Oral January 2024
Butalbital Combo January 2024
Camzyos January 2024
Corlanor January 2024
Empaveli January 2024
Enjaymo January 2024
HBV Nucleotide Analog Reverse Transcriptase Inhibitors January 2024
High Risk Therapies January 2024
Morphine Milligram Equivalent Accumulation January 2024
Non-Oral Contraceptives January 2024
Selzentry January 2024
Skysona January 2024
Tavneos January 2024
Transmucosal Immediate Release Fentanyl (TIRF) January 2024
Verquvo January 2024
Zynteglo January 2024
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Anti-Amyloid Monoclonal Antibody January 2024
Antipsychotics - 1st Generation (Typical) January 2024
Auvelity January 2024
C5 Complement Inhibitors January 2024
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators January 2024
Duchenne Muscular Dystrophy (DMD) January 2024
Hemophilia Gene Therapy Agents January 2024
Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) Stabilizers January 2024
Opioids – Short-Acting January 2024
Sohonos January 2024
Ztalmy January 2024
DUR Criteria
Resource List - New or Revised Criteria
Media
Antipsychotics - 2nd Generation (Atypical) Depot Agents January 2024
Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents January 2024
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Alzheimer’s Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists & Combinations January 2024
Antibiotics, Mupirocin Topical January 2024
Anti-Migraine, Serotonin (5-HT1) Receptor Agonists January 2024
Anti-Parkinsonism, MAO-B Inhibitors January 2024
Anti-Parkinsonism, Non-Ergot Dopamine Agonists January 2024
Calcitonin Gene-Related Peptide (CGRP) Inhibitors January 2024
Cephalosporin Agents January 2024
Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors January 2024
Fluoroquinolones, Oral January 2024
Hereditary Angioedema Agents January 2024
Macrolides January 2024
NSAIDs January 2024
Opioids, Long Acting January 2024
Penicillin Agents January 2024
Somatostatin Analogs January 2024
Tetracyclines January 2024
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Antiandrogenic Agents January 2024
Antibiotics, Gastrointestinal (GI) January 2024
Antibiotics, Vaginal January 2024
Anticonvulsants, Dravet Syndrome January 2024
Antiemetics, 5-HT3 and NK1 Injectables January 2024
Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables January 2024
Anti-Migraine, Alternative Agents January 2024
Antiretroviral Therapy (ART) January 2024
Fibromyalgia Agents January 2024
GI Motility Agents, Chronic January 2024
Glucagon Agents January 2024
Mitogen-activated Extracellular Kinase Inhibitors (MEKi) & B-raf Kinase Inhibitors (BRAFi) January 2024
Neuropathic Pain Agents January 2024
Opioid & Select Alcohol Dependence Agents January 2024
Opioid Emergency Reversal Agents January 2024
Sedative Hypnotics January 2024
Skeletal Muscle Relaxants January 2024
Systemic Enzyme Inhibitors, FGFR Inhibitors January 2024
Tramadol-Like Agents January 2024
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors January 2024
Page
Drug Prior Authorization Committee Meeting Information